Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
29.79
-0.24 (-0.80%)
At close: Oct 26, 2026, 4:00 PM EDT
29.74
-0.05 (-0.17%)
After-hours: Oct 26, 2026, 7:59 PM EDT
Pfizer Market Cap
Pfizer has a market cap or net worth of $169.79 billion as of October 26, 2026. It is the 113th most valuable company in the world and the 74th biggest in the United States. Its market cap has increased by 20.61% in one year.
Market Cap
169.79B
Enterprise Value
221.57B
1-Year Change
20.61%
Global Rank
Country Rank
#74 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Pfizer's market cap has increased from $144.06B to $169.79B, an increase of 17.87%. That is a compound annual growth rate of 0.59%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 26, 2026 | 169.79B | 19.93% |
| Dec 31, 2025 | 141.57B | -5.83% |
| Dec 31, 2024 | 150.35B | -7.51% |
| Dec 29, 2023 | 162.56B | -43.48% |
| Dec 30, 2022 | 287.63B | -13.22% |
| Dec 31, 2021 | 331.44B | 61.99% |
| Dec 31, 2020 | 204.60B | -5.64% |
| Dec 31, 2019 | 216.83B | -14.07% |
| Dec 31, 2018 | 252.32B | 16.87% |
| Dec 29, 2017 | 215.90B | 9.54% |
| Dec 30, 2016 | 197.10B | -1.09% |
| Dec 31, 2015 | 199.26B | 1.53% |
| Dec 31, 2014 | 196.27B | -1.13% |
| Dec 31, 2013 | 198.52B | 7.51% |
| Dec 31, 2012 | 184.65B | 11.00% |
| Dec 30, 2011 | 166.35B | 18.60% |
| Dec 31, 2010 | 140.25B | -4.45% |
| Dec 31, 2009 | 146.78B | 22.92% |
| Dec 31, 2008 | 119.42B | -23.08% |
| Dec 31, 2007 | 155.24B | -16.87% |
| Dec 29, 2006 | 186.75B | 8.64% |
| Dec 30, 2005 | 171.90B | -15.11% |
| Dec 31, 2004 | 202.51B | -24.89% |
| Dec 31, 2003 | 269.62B | 43.13% |
| Dec 31, 2002 | 188.38B | -24.81% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 635.07B |
| AbbVie | 504.76B |
| Merck & Co. | 358.41B |
| Novartis AG | 294.91B |
| AstraZeneca | 266.06B |
| Amgen | 237.48B |
| Gilead Sciences | 193.48B |
| Novo Nordisk | 172.38B |